CSBio CSBio

X
[{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Debiopharm\\'s Novel Chemo-Radio Sensitizer Debio 1143","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Debiopharm"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn announces FDA acceptance of IND application for TAS0953\/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Dosed First Patient in Pivotal Ph 2 Portion of LOTIS 3 Trial of Loncastuximab Tesirine in Combination With Ibrutinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Submits BLA to the U.S FDA for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ADC Therapeutics"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals Announces Publication of Clinical Data from the Phase I\/Ib study of Tenalisib in Patients with Relapsed\/Refractory T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Interim Results from Phase 1\/2 Study Fides-02 Exploring Derazantinib in Patients with Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Preclinical Data on Anti-Angiogenic Activity of Derazantinib at ENA 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for Ramucirumab in the Ongoing Fides-03 Study with Derazantinib in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts ADC Therapeutics' BLA, Grants Priority Review for Loncastuximab Tesirine for Relapsed\/Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ADC Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Derazantinib\/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding part of FIDES-02 Study in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Gets CTA Approval to Start Phase I\/II Study to Evaluate the Safety, Dosing and Clinical Activity of ANV419 in Solid Tumors Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Anaveon"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Numab Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Gets U.S. FDA Orphan Drug Designation for Lisavanbulin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Preclinical Data on Synergy Between Derazantinib and Paclitaxel in Gastric Tumor Models At ANE Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I\/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"Anaveon","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$119.6 million","upfrontCash":"Undisclosed","newsHeadline":"Anaveon to raise CHF 110 million in oversubscribed Series B financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Anaveon"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Lonza Group"},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Presents Compelling Data From the Phase I\/II Study of ANV419 During the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Anaveon"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Nouscom AG"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pivotal Data Demonstrate Clinical Benefit of Roche\u2019s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data at the 2022 ASCO Annual Meeting Highlight Roche\u2019s Continued Commitment to Innovation in Oncology and Personalised Healthcare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Helsinn's Oncology Pipeline Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Nouscom AG"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Roche's Lunsumio for People With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Presents Newly Available Data on Vepafestinib at IASCLC 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Leading Publication Revealing an Immune Mechanism of Action Driving Anti-tumor Activity of Adenovirus Vectored Vaccines and Anti-PD1 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Nouscom AG"},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Presents Updated Data From the Phase I\/II study of ANV419 during the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Anaveon"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ichnos Sciences"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR\/MSI-High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Nouscom AG"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Initiates Phase Ib Pancreatic Cancer Trial of Next-Generation Autotaxin Inhibitor IOA-289","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ionctura"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Council","pharmaFlowCategory":"D","amount":"$18.5 million","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Awarded EUR17.5 Million Funding from The EIC Accelerator For Clinical Development of Novel Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ionctura"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review To Roche\u2019s Bispecific Antibody Glofitamab For People With Relapsed Or Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Doses First Patient in A Phase I\/II Study of ANV419 as Monotherapy or In Combination with Check Point Inhibitors in Patients with Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Anaveon"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) antibody Innate Cell Modulator, ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Ichnos Sciences"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Announces Launch of The Phase 1\/2 GaLuCi\u2122 Study for Its CA IX-Targeted Radiopharmaceutical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches Phase 1\/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Debiopharm"}]

Find Oncology Drugs in Phase I/II Clinical Development in SWITZERLAND

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor, it is being investigated in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.

            Lead Product(s): Debio 0123,Temozolomide

            Therapeutic Area: Oncology Product Name: Debio 0123

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Debio 0328 ([68Ga]Ga-DPI-4452) and Debio 0228 ([177Lu]Lu-DPI-4452) are the only peptide-based theranostic pair targeting CAIX in clinical development, with pan-tumor potential, and developed first for patients with advanced cancers such as renal, pancreatic, and colorectal.

            Lead Product(s): [68Ga]Ga-DPI-4452,[177Lu]Lu-DPI-4452

            Therapeutic Area: Oncology Product Name: Debio 0328

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ISB 1442 is a biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47, for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).

            Lead Product(s): ISB 1442

            Therapeutic Area: Oncology Product Name: ISB 1442

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ANV419, is a selective interleukin-2 (IL-2) receptor agonist which can selectively promote the function of immune effector cells, making it a potential treatment for a range of cancer types.

            Lead Product(s): ANV419,Pembrolizumab

            Therapeutic Area: Oncology Product Name: ANV419

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RO7082859 (Glofitamab) is an investigational CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells, activating the release of cancer cell-killing proteins from the T-cell.

            Lead Product(s): Glofitamab,Obinutuzumab,Tocilizumab

            Therapeutic Area: Oncology Product Name: RO7082859

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IOA-289 is the first ATX inhibitor in clinical development for cancer. It is an oral small molecule non-competitive inhibitor with novel binding chemistry and a safe clinical profile. Inhibiting ATX with IOA-289 directly prevents the proliferation of cancer cells.

            Lead Product(s): IOA-289,Gemcitabine,Paclitaxel

            Therapeutic Area: Oncology Product Name: IOA-289

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: European Investment Council

            Deal Size: $18.5 million Upfront Cash: Undisclosed

            Deal Type: Funding December 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Glofitamab (RO7082859), is an investigational CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells.

            Lead Product(s): Glofitamab,Obinutuzumab,Tocilizumab

            Therapeutic Area: Oncology Product Name: RO7082859

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IOA-289 is an orally dosed small molecule that has been shown preclinically to have a multi-pronged approach to treating cancer, acting directly to prevent proliferation of tumor cells and indirectly to potentiate the actions of the immune system.

            Lead Product(s): IOA-289,Gemcitabine,Paclitaxel

            Therapeutic Area: Oncology Product Name: IOA-289

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NOUS-209 (GAd-209-FSP) is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors, generates highly immunogenic neoantigens called frame shift peptides (FSP) that are not present in healthy tissue.

            Lead Product(s): GAd-209-FSP,Pembrolizumab

            Therapeutic Area: Oncology Product Name: NOUS-209

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody.

            Lead Product(s): ISB 1442

            Therapeutic Area: Oncology Product Name: ISB 1442

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY